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Radiocontrast-induced nephropathy in humans: Role of renal vasocon-
striction. Radiocontrast-induced nephropathy (RCIN) is a common
cause of acute renal failure in hospitalized patients. Renal vasoconstric-
tion figures prominently in the proposed pathogenesis of RCIN based
on animal experiments. Prior human studies examining renal hemody-
namic changes after contrast medium (CM) injection are inconclusive.
No previous study of animals or humans has established a relationship
between CM-associated renal hemodynamic changes and the subse-
quent development of RCIN. In the present study, we examined the
renal hemodynamic effects of CM in patients at high risk of RCIN. In
addition, we related those effects to the subsequent development of
RCIN. Using renal vein thermodilution catheters, we measured renal
blood flow (RBF) in 12 patients with chronic renal failure [serum
creatinine (Sr)  159 mo1/literI during ionic CM injection for cardiac
catheterization. We made measurements at the start of the procedure (t
= 0), before the ventriculogram (t = 5), after the ventriculogram (t
15), and after the coronary angiogram (t = 65). We measured Sc,. at t =
0 and again 24 and 48 hours later. Mean RBF for the group tended to
increase after the ventriculogram, and increased significantly by t = 65
(P < 0.005 vs. t = 0). When examined by individual patient, RBF fell
below baseline in three patients (30%) at t = 15, but rose above baseline
again by t = 65. Only one patient (8.3%) had a fall in RBF below
baseline at t = 65. RCIN (defined as an increase in Se,. 25% above
baseline) developed in six patients (50%) within 48 hours. Of those only
two (33%) had shown a fall in RBF at t = 15, and none at t = 65, Of the
four patients in the group as a whole whose RBF had fallen at any time,
only two (50%) developed RCIN. We conclude that intracardiac injec-
tion of ionic CM is not associated with a fall in total RBF in most
patients with chronic renal failure. Furthermore, there appears to be no
relationship between the development of RCIN and any change in total
RBF. Global renal vasoconstriction does not appear to play a patho-
genic role in RCIN in humans with chronic renal failure.
Radiocontrast induced nephropathy (RCIN) is an important
cause of acute renal failure [1, 2]. Pre-existing renal insuffi-
ciency increases the risk of developing RCIN [3—71. Therapeu-
tic maneuvers designed to reduce the risk of RCIN in humans
thus far have been disappointing. In particular, a beneficial
effect of non-ionic contrast medium (CM) has not been clearly
demonstrated [3—5, 8, 9].
The rational development of effective prophylactic regimens
for RCIN will depend on a complete understanding of its
pathogenesis. Prominent among the current pathogenic formu-
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lations is the role of renal vasoconstriction [10, 11], This
proposed mechanism owes its popularity to a number of studies
in animals [12—17] showing an abrupt increase followed by a
decrease in global renal blood flow (RBF) after CM injection.
Whether CM has such a renal hemodynamic effect in humans
is not clear. Most data in this area derive from studies in
humans using para-amino hippurate (PAH) infusion to estimate
RBF [18—211, a method of questionable validity in the presence
of iodinated CM [20, 22, 23]. Studies using other RBF measure-
ment techniques in humans are few and contradictory [24, 25].
There are four "multiple insult" animal models of RCIN
[26—29], however, none of the data derived from them permits
any inference about the pathogenic role of contrast-induced
renal hemodynamic changes. In human experiments, changes in
RBF during CM infusion have never been correlated with the
subsequent development of RCIN.
We therefore designed the present study to answer two
questions: (1) Is intravascular CM injection associated with an
immediate decrease in global RBF in humans? and, if so, (2) Is
there a relationship between immediate contrast-induced renal
vasoconstriction and the subsequent development of RCIN?
We chose to study a population of patients we have previously
shown to be at high risk for RCIN: patients with chronic renal
insufficiency undergoing cardiac catheterization [7]. We mea-
sured changes in global renal blood flow during cardiac cathe-
terization using a renal vein thermodilution catheter. In addition
we monitored renal function in these same patients for several
days to detect the development of RCIN. Our results demon-
strate that CM injection is not predictably associated with
global renal vasoconstriction in humans with chronic renal
insufficiency, and that there is no relationship between global
renal vasoconstriction and the subsequent development of
RCIN.
Methods
Patient selection
All patients with chronic renal failure, defined as a stable
serum creatinine concentration (Sr) greater than or equal to
159 lLmollliter (1.8 mg/dl), undergoing elective cardiac catheter-
ization were considered eligible for inclusion in the study.
Patients were specifically excluded if they had New York Heart
Association Class IV congestive heart failure, hepatic disease,
hemodynamic instability, allergy to CM, prior CM exposure
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Fig. 1. Radiograph showing thermodilution
catheter in the left renal vein (solid arrow). A
Swan-Ganz catheter is seen in the inferior
vena cava (open arrow). Note that the
thermistor (tip of solid arrow) lies well within
the renal vein.
within seven days of the experimental protocol, or were preg-
nant. Before enrollment in the study all patients gave informed
written consent to participate in the research protocol approved
by the Institutional Review Board at Cooper Hospital/Univer-
sity Medical Center. A medical history was taken and a physical
examination performed with specific attention to the exclusion
criteria, medications and the etiology of chronic renal failure.
Experimental protocol
All patients had Sr measured upon entry into the study.
Intravenous 75 m sodium chloride was infused at 100 mI/hr
beginning 12 hours before, and continuing throughout, the
cardiac catheterization. At no time did patients receive manni-
tol. Cardiac catheterization was performed by the percutaneous
femoral approach in the fasting state. One arterial and two
venous sheaths were placed and baseline S. was measured
(time 0, t = 0). A catheter was advanced into the left renal vein
for serial measurements of RBF (see below). A Swan-Ganz
thermodilution catheter was advanced into the pulmonary ar-
tery for serial determinations of cardiac output and right heart
pressures. A pigtail catheter was advanced into the left ventri-
cle for ventriculography. All patients underwent a single yen-
triculogram (completed by about 15 minutes, t = 15) followed
by coronary angiography (completed by about 65 minutes, t
65). The CM used in all cases was MD76 (66% diatrizoate
meglumine, 10% diatrizoate sodium). A record was made of all
hemodynamic changes and medications administered during the
catheterization as well as the total volume of CM infused.
Measurement of renal blood flow
RBF was measured using a 7-French dual thermistor ther-
modilution catheter (Webster Labs, Baldwin Park, California,
USA) introduced through the femoral vein via an indwelling
introducer and fluoroscopically guided into the left renal vein.
We chose to catheterize the left renal vein since it is longer than
the right, about three times as long as the distance from the tip
of the thermodilution catheter to the external thermistor. In this
way, we ensured that the external thermistor remained well
within the renal vein throughout the protocol (Fig. 1). The
position of the catheter in the renal vein was confirmed by
documenting a step-up in oxygen saturation of blood withdrawn
through the catheter. We documented saturation greater than
80% in all cases, confirming position in the renal vein [30]. In
addition, we checked the position of the catheter fluoroscopi-
cally several times during each protocol. We used a continuous
thermodilution technique for RBF determinations as reported
previously [71. Room-temperature 5% dextrose was infused
through the catheter with a Harvard pump (Harvard Apparatus
Co., Millis, Massachusetts, USA) at a constant rate of 50
ml/min until the deflections of both thermistors consequent to
the thermodilution temperature changes were stable. This
method has been shown to accurately and reproducibly mea-
sure momentary increases and decreases in renal blood flow [7,
30—32]. Three or four replicate RBF measurements were made
at approximately one-minute intervals for each time point. In
one patient, we measured RBF nine times between 20 seconds
and eight minutes following the ventriculogram. RBF was
measured at t = 0, t = 5 (before the ventriculogram), t = 15
(immediately after the ventriculogram), and t = 65 (after the
coronary angiogram).
Laboratory measurements
A blood specimen for Sr was obtained upon entry into the
study. Sr measurement was repeated at t = 0, 24 hours after
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Table 1. Baseline patient characteristics
Patient Age Sex Sr f2moluite,' CCcr mi/mm Diseasea Medication&'
#1 80 F 203 11 RhHD prop, LSDN
#2 60 M 239 40 ADPKD ISDN
#3 72 M 168 34 CHF ver, furos, dig
#4 68 M 248 34 HTN metop, nifed
#5 64 F 327 16 DM, HTN nicard, bumet
#6 72 F 301 17 DM, HTN dilt, ISDN
#7 54 M 168 52 HTN labet, dilt
#8 70 M 292 27 DM, HTN dilt, ISDN
#9 76 F 212 18 HTN, CHF dilt
#10 73 F 301 18 DM ASA
#11 59 F 274 19 DM, HTN furos, nifed
#12 63 M 203 36 DM dig, ver
Mean 67.6 248 26.7
SEM 2.2 18 3.6
Abbreviations are: Sc,., serum creatinine concentration; CCcr, calculated creatinine clearance, according to the formula of Cockcroft and Gault
[33].
a RhHD, rheumatic heart disease; ADPKD, autosomal-doininant polycystic kidney disease; HTN, hypertension; DM, diabetes mellitus; CHF,
congestive heart failure.b prop, propranolol; ISDN, isosorbide dinitrate; ver, verapamil; furos, furosemide; dig, digoxin; metop, metoprolol; nifed, nifedipine; nicard,
nicardipine; bumet, bumetanide; dilt, diltiazem; labet, labetalol; ASA, aspirin.
the catheterization and daily thereafter until the Se,. value
returned to the baseline level or stabilized. SC,. was determined
by a modified Jaffe end-point assay in an Hitachi 737 autoana-
lyzer (Boehringer-Manheim, Indianapolis, Indiana, USA). We
defined RCIN as a rise in Se,. of at least 25% 48 hours after the
cardiac catheterization.
Statistical analysis
All continuous data were tabulated and analyzed as mean
SEM. Paired t-tests were used to determine differences between
two time points. Differences were considered to be significant
when P was less than 0.05.
Results
Clinical characteristics
Twelve patients met the study criteria for enrollment and
completed the described protocol. The clinical characteristics
of the patients are shown in Table 1. Nine of the 12 patients
were taking calcium channel blockers on a long-term basis. The
mean total dose of CM was 145.1 11.6 ml, the ventriculogram
accounting for 28 to 45 ml of that amount.
Renal and systemic hemodynamics
The mean coefficient of variation for all replicate RBF
measurements in our laboratory is 9.1%. The mean coefficient
of variation at low RBF (<200 mllmin) was not significantly
different than at high RBF (200 mllmin) (8.5 0.9% vs. 10,1
0.8%, respectively, P 0,24). All patients had RBF mea-
surements made at t = 0, t = 5 and t 65. Two patients (#9 and
#11) did not have RBF measured at t 15 for technical
reasons.
Figure 2 shows mean percent change in RBF for all patients
over time. RBF tended to rise after the ventriculogram (121
53%), and the increase reached significance after the coronary
angiogram (176 94%, P < 0.005 vs. t 0). Figure 3 shows
absolute RBF by individual patient over time. Compared with
the t = 0 value, RBF rose or remained constant in all but three
patients (#3, #5 and #7) immediately following the ventriculo-
gram (t = 15). In those three patients, RBF fell by 16%, 13%
and 16%, respectively, If t 5 is taken as the baseline, no
patient sustained a fall in RBF after the ventriculogram. At t
65, after coronary angiography, only one patient (#12) showed
a decline in RBF (by 19%) compared with the measurement at
t = 0 or t = 5. Of the patients who were taking no calcium
channel blocker (#1, #2 and #10), none had a fall in mean RBF
below baseline at any time point.
Figure 4 shows the actual replicate measurements made for
each patient following the ventriculogram. The ventriculogram
was performed at t 15 and the replicate measurements made
at approximately one-minute intervals beginning less than one
minute after CM injection. One patient (#12) had nine separate
measurements made over eight minutes beginning 20 seconds
after CM injection. RBF tended to remain stable after exposure
to a discrete injection of CM.
The average mean arterial pressure (MAP) at baseline was
108 13 torr and remained constant throughout the protocol,
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Fig. 2. Mean percent change in RBF during cardiac catheterization for
all patients. Mean RBF at t = 0 is 100%. p z 0.05 vs. t = 0 (paired
t-test).
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Fig. 3. Absolute RBF during cardiac
catheterization, by individual patient. Line
labels at right correspond to patient number in
Table 1. Ventriculogram was performed at
approximately t = 14. Coronary angiogram
was performed between approximately t = 20
and t = 60. Each point represents the mean of
three or four replicate RBF measurements
made within approximately one minute of
each other.
except for the usual transient dip in MAP immediately after CM
injection for both the ventriculogram and coronary angiogra-
phy, lasting less than 30 seconds [341. In all cases but one (#12,
after the ventriculogram) RBF measurements were made more
than 30 seconds after the CM injection, when MAP had
returned to baseline. Mean cardiac output for the group at
baseline was 4.61 1.2 liter/mm and remained constant until t
= 65 at which time it rose to 5.1 1.5 liter/mm (P < 0.05 vs. t
= 0). Mean renal vascular resistance (calculated as RVR =
(MAP — RAP) ÷ RBF, where RAP is right atrial pressure) at
= 65 was 67 7% of the mean baseline value, a significant
decline (P < 0.001).
Serum creatinine concentration
Figure 5 shows SCr at baseline and 48 hours after cardiac
catheterization. Sr rose by more than 25% in six of the 12
patients (#1, #3, #4, #5, #8, #11). Three patients, all of whom
had diabetes mellitus, required dialysis (#5, #8, #11). Of the
six patients who developed RCIN, two (#3, #5) had shown a
significant decrease below baseline RBF after the ventriculo-
gram, however, RBF for all six patients who developed RCIN
was at or above baseline at t = 65 (Fig. 6). Of the four patients
in the group as a whole whose RBF fell with respect to baseline
at any time after radiocontrast infusion, only two developed
RCIN (#3 and #5).
Discussion
We studied the global renal hemodynamic effects of CM
injection in patients at high risk of developing RCIN: patients
with chronic renal insufficiency. In addition, we attempted to
define the relationship between global renal hemodynamics
following CM injection and the subsequent development of
RCIN in this high-risk population.
Our results demonstrate clearly that intracardiac ionic radio-
contrast medium does not tend to cause a decrease in overall
RBF in humans with impaired renal function. On the contrary,
mean RBF for the group as a whole increased after exposure to
CM (Fig. 2).
Most of the data derived from animal experiments indicate
maximal vasoconstriction at about 40 seconds after CM injec-
tion. The duration of the vasoconstriction is highly variable,
lasting from one minute after a single injection [12—16] to over
3½ hours after repeated contrast injections [17]. Studies in
humans have shown a decrease in PAH extraction or clearance
lasting between two and 60 minutes [18—21]. The magnitude of
the reported decrease ranges between 10 and 50 percent, the
most common decrement being about 20 percent, well within
the range detectable by the thermodilution method [7, 30—32].
To examine the immediate effect of a discrete CM injection
on RBF we analyzed the individual replicate RBF measure-
ments made at approximately one minute intervals following
the ventricutogram (Fig. 4). RBF remained essentially stable
and unchanged from the pre-injection level. A significant mo-
mentary hemodynamic perturbation might have occurred
within the first minute; however, we noted no such effect in the
one patient whose RBF was measured beginning 20 seconds
after CM injection. Thus, a discrete intracardiac injection of
ionic CM was not associated with global renal vasoconstriction
in this population.
Mean RBF was significantly higher at t = 65 than at baseline,
coronary
angiogram
1000
800
600
400
ventriculogram
U-
200
151
I I
0 5 15
Time, minutes
65
E
0)C
C
0)
E
0)
. .
Fig. 4. Absolute RBF over time, by individual
patient, immediately following the
______________________________________________________________________
ventriculogram (at 0 mm). Line labels at leftI I I ' '
correspond to patient number in Table 1.
1 2 3 4 5 6 7 8 Circled numbers refer to patients taking no
calcium channel blockers. Each point
Time, minutes represents a single RBF measurement.
and when analyzed by individual patient RBF rose or remained
constant in 11 of 12 patients (92%). Thus repeated injections of
CM did not cause global renal vasoconstriction.
Half the patients developed RCIN by our criterion. This is
similar to the incidence we [7] and others [61 have reported
previously in comparable "high-risk" patients. If global renal
vasoconstriction were important in the pathogenesis of RCIN
we would have expected those patients whose Sc rose to have
shown a fall in overall RBF below their baseline after CM
injection. In fact, however, of the six patients whose Sr rose,
only two had a transient decrease in RBF after the ventriculo-
gram, and none showed a fall below baseline at t = 65 (Fig. 6).
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Fig. 5. Change in serum creatinine
concentration after cardiac catheterization, by
individual patient. Time 0 hours corresponds
to t 0 in Figures 1 and 2. Line labels at
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Similarly, of the four patients whose RBF fell below baseline at
any time during the protocol, two maintained stable renal
function. Thus, there is no predictable relationship between
radiocontrast-associated global renal vasoconstriction and
RCIN in this high-risk population.
While most animal investigations of the renal hemodynamic
effects of CM have shown vasodilation followed by vasocon-
striction of variable duration [13—16, 35, 361 this finding is not
universal. Indeed, two separate studies using an electromag-
netic flow probe to measure RBF in dogs showed a tendency for
RBF to rise following CM injection [23, 29]. Furthermore, a
recent study in pigs in which RBF was measured by renal vein
thermodilution catheter demonstrated no change in RBF after
high-dose ionic or non-ionic CM injection [37].
Prior human studies of the renal hemodynamic effects of CM
are few and equivocal. When RBF was measured by Xenon
washout no effect on RBF was discernible 30 minutes after
aortography [25]. Using a dye-dilution method, Aperia, Bro-
berger and Ekengren reported a significant decline in RBF one
minute after renal arteriography in five children, four of whom
had CRF [24]. Other studies in humans employing PAH clear-
ance or extraction to estimate RBF have shown a decrease of
variable duration after CM injection [21, 38, 39]. However,
hippurate may not be a valid tool for estimating RBF in the
presence of iodinated CM. CM immediately decreases renal
PAH extraction in humans [19, 20] and dogs [12, 23, 40], a
reversible effect which can be dissociated from changes in RBF
and which probably represents a direct inhibition of tubular
transport [22].
Thus, neither in animals nor much less in humans is the renal
vasoconstrictive effect of CM established. Our results suggest
Fig. 6. Absolute RBF over time in patients
65 who developed RCIN. See Figure 3 legend for
details. Patient #11 had no measurement of
RBF at t = 15 for technical reasons.
quite the contrary: that CM injection is not associated with
diminished total RBF in humans.
Global renal vasoconstriction has figured prominently in the
proposed pathogenesis of RCIN based largely on circumstantial
evidence from animal experiments [10, 11]. The difficulty in
establishing a causal relationship between renal vasoconstric-
tion and renal failure has resulted from the remarkable resis-
tance of experimental animals to radiocontrast-induced renal
failure. Four animal models of RCIN now exist [26—29] and
three have been used to explore the pathogenic role of renal
vasoconstriction. Lund et al were unable to demonstrate a
correlation between degree of pathologic damage and the
contrast-induced decrease in RBF in a canine preparation [26].
In rabbits with established RCIN, RBF was no different from a
control group. The immediate renal hemodynamic effects of
CM were not assessed in that study [27]. Finally, Margulies et
al found no decline in RBF after intra-aortic injection of CM;
indeed, there was a tendency for RBF to increase during the
CM infusion [29].
In summary, no previous animal studies have shown a
pathogenic role for global renal vasoconstriction in RCIN. No
previous studies in humans have explored the question. The
present data suggest that the development of RCIN in humans
is not dependent on global renal vasoconstriction and con-
versely, that renal vasoconstriction following CM injection
does not necessarily predispose to RCIN in high-risk patients.
Nine of the 12 patients we studied were taking calcium
channel blockers on a long-term basis at the time of the
protocol. The evidence that calcium channel blockers may
prevent RCIN in humans is equivocal [6, 41, 42]. In the present
study, five of the six patients who developed RCIN were taking
ventriculogram
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calcium channel blockers. 5cr remained stable in two of the
three patients taking no calcium channel blocker. Nonetheless,
our sample size is too small to assess the statistical significance
of any effect of calcium channel blockers on the development of
RCIN.
In the setting of normal renal function, an acute dose of a
calcium channel blocker may mitigate the CM-associated renal
hemodynamic effects seen by some investigators [21, 43, 441.
However, patients with renal impairment appear to be largely
resistant to the renal vasodilatory effect of an acute i.v. dose
[45] or long-term administration [45—50] of calcium channel
blockers. Whether these drugs, given long-term, might modify
the renal hemodynamic response to CM in patients with renal
impairment has not been addressed systematically in prior
studies, nor in the present study. In our population, of the three
patients taking no calcium channel blockers, none had a fall in
RBF below baseline at any time during the cardiac catheteriza-
tion.
Irrespective of any possible confounding effect of calcium
channel blockers on renal hemodynamics, the present study
strongly suggests that global renal vasoconstriction does not
have a pathogenic role in human RCIN. Only two of the six
patients who developed RCIN had even a transient decrease,
and none had a sustained decrease, in RBF during the cathe-
terization (Fig. 6).
The results of our study do not argue against a role for renal
ischemia in the pathogenesis of RCIN. CM infusion may result
in intrarenal redistribution of RBF leading to medullary isch-
emia undetectable by measurements of global RBF. Such a
mechanism is suggested by the multiple-insult rat model of
RCIN in which pathologic injury is confined largely to the outer
medulla [28], a region of the kidney on the verge of anoxia
under normal circumstances [51]. Measurement of regional
RBF by laser Doppler flowtometry during CM infusion into rats
shows a shift of blood flow from the medulla to the cortex [52],
supporting this mechanism. A deleterious effect of CM injection
on medullary blood flow is further supported by a recent study
showing that radiocontrast-induced pathologic and functional
damage in rats may be modulated by manipulating the nitric
oxide system, which appears to participate in the regulation of
medullary blood flow and oxygen balance [53]. Further empha-
sizing that CM-induced damage may result from an imbalance
of medullary oxygen supply and consumption is the observation
that furosemide mitigates medullary injury in the rat model of
RCIN [54], presumably by decreasing medullary oxygen con-
sumption. Two studies in humans examining RBF redistribu-
tion following CM injection have yielded conflicting results [25,
55].
In summary, intracardiac injection of ionic CM is not asso-
ciated with a fall in global RBF in most patients with chronic
renal failure. Furthermore, there appears to be no relationship
between the development of acute RCIN and any change in
global RBF. Additional studies are needed to define the patho-
genic role of intrarenal redistribution of blood flow and renal
oxygen economy in humans.
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